Professional
Added to YB: 2024-04-11
Pitch date: 2024-04-01
ACHV [bullish]
Achieve Life Sciences, Inc.
-1.32%
current return
Author Info
DF Research shares (mostly) short-biased research from Dalrymple Finance. Sign up for the newsletter.
Company Info
Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom.
Market Cap
$149.2M
Pitch Price
$4.55
Price Target
40.00 (+762%)
Dividend
N/A
EV/EBITDA
-2.09
P/E
-2.00
EV/Sales
N/A
Sector
Biotechnology
Category
special_situation
Achieve Life Sciences - A Long Report
ACHV: Smoking cessation drug Cytisinicline, derived from plant, through Phase 3 trials. Increases quit odds 4-6x vs placebo, superior to competition. Well tolerated, excellent safety. NDA likely 1H25, potential $20-$40/share buyout. 4-9x upside.
Read full article (2 min)